All Videos

Experts in dermatology share their insights on how to approach corticosteroid hesitancy in their dermatology patient populations.

Experts in dermatology discuss their considerations for atopic dermatitis and plaque psoriasis topical treatment options highlighting the different penetration, access, and safety considerations.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C comment on the practical aspects of utilizing topical corticosteroids, including potency, formulation, administration, and utility.

James Q Del Rosso, DO and TJ Chao, MPAS, PA-C discuss the role of topical agents in the management of dermatological conditions reviewing their position and role within the treatment landscape for dermatological conditions.

Chesahna Kindred, MD, MBA, FAAD, and Renata Block, PA-C, describe how ruxolitinib works differently from other topicals traditionally used in the treatment of vitiligo.

Experts review the benefits and adverse effects of off-label treatments for patients with vitiligo such as corticosteroids, tacrolimus, pimecrolimus, or calcipotriene (in combination with corticosteroids).

Raj Chovatiya, MD, PHD, and Boni Elewski, MD, discuss long-term treatment selection for a patient whose GPP flare cleared with 1 infusion of spesolimab.

Boni Elewski, MD, reviews a case of a woman in the emergency department with a severe GPP flare.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss pearls and key take-aways from their experience managing atopic dermatitis. Jennifer Holman wraps up discussing anticipated therapeutic developments and unmet needs.

Jennifer Holman, MD, FAAD, reflects on the improvements in therapeutic treatments and outcomes for patients like Audrey Dean, and how her experience and quality of life has also improved with these medical advances.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss how treatment with upadacitinib for atopic dermatitis has improved her quality of life.

Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Experts explain their approach to the treatment of a new patient with vitiligo and the role of phototherapy in their practice.

Chesahna Kindred, MD, MBA, FAAD, reviews mental health issues that patients with vitiligo are at increased risk for.

Boni Elewski, MD, shares her personal experience using generalized pustular psoriasis treatments in the clinical setting.

Drs Raj Chovatiya and Boni Elewski discuss a patient case and the challenges of diagnosing generalized pustular psoriasis (GPP), commenting on the many types of psoriasis and treatment.

Audrey Dean discusses her experience of atopic dermatitis therapeutic side effects with her dermatologist, Jennifer Holman, MD, FAAD. Jennifer Holman goes on to highlight key pearls on managing patients with atopic dermatitis.

Audrey Dean discusses with her dermatologist, Jennifer Holman, MD, FAAD, how supportive therapies and dietary changes have altered her disease severity. Jennifer Holman goes on to highlight a wholistic approach to treatment, and how treating atopic dermatitis can have a multidisciplinary approach.

Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.

Experts in dermatology review unmet needs in the plaque psoriasis treatment landscape, as well as ongoing studies coming down the pipeline.

Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).

Christopher Bunick, MD, PhD, discusses how a patient’s atopic dermatitis (AD) endotype may alter treatment approaches in the future.

Experts offer their clinical advice on when and how to transition patients from a biologic or immunosuppressive agent to a Janus Kinase (JAK) inhibitor.

Renata Block, PA-C, analyzes a study on how vitiligo affects different socioeconomic groups disproportionately.

Gary M. Owens, MD, discusses the economic costs associated with vitiligo and the impact this disease has had on the US health care system in general.

Expert dermatologists review a case of a 61-year-old female patient with GPP with no personal or family history of the condition.

Raj Chovatiya, MD, PhD; and Boni Elewski, MD, reviews the many pathways of generalized pustular psoriasis (GPP), focusing on individualizing therapy for patients with GPP and treatment options.

Jennifer Holman, MD, FAAD, and her patient, Audrey Dean, discuss Audrey’s initial diagnosis experience. Jennifer Holman goes on to describe how different patient populations struggle to access quality care.

Lakshi Aldredge, MSN, ANP-BC, and Jennifer Conner, MPAS, PA-C, share treatment approaches to metabolic syndrome as a comorbidity with plaque psoriasis.